PHOENIXVILLE, Pennsylvania.–(BUSINESS WIRE)—Affinity Bio Partners and Affinity BioCeuticals, CEO, Christina DiArcangelo Puller announced that they are hosting the 1st Medical Cannabis Clinical Symposium in Philadelphia, PA on December 8, 2017.
“Affinity Bio Partners and Affinity BioCeuticals’ are very proud to facilitate the 1st Annual Clinical Research Industry Leaders Conference for Medical Cannabis Clinical Research. This Symposium is designed to promote Medical Cannabis Education and empower medical professionals to step out of the “Green Closet” and step into Medical Cannabis Clinical Research. It is with great importance to ensure that the levels of education and professionalism are raised in the ever-evolving medical cannabis industry. ” said Christina DiArcangelo Puller, CEO, Affinity Bio Partners and Affinity BioCeuticals.
To review the symposium brochure and purchase tickets, please visit
Forward Looking Statements:
Statements in this document that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “goal,” “focus,” “aims,” “believes,” “can,” “challenge,” ”predictable,” “will,” or the negative of these terms or other comparable terminology. We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make.